logo

BCDA

Biocardia·NASDAQ
--
--(--)
--
--(--)

BCDA fundamentals

Biocardia (BCDA) released its earnings on Mar 24, 2026: revenue was 0 (YoY -100.00%), met estimates; EPS was 0 (YoY +100.00%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
0
+100.00%
Report date
Mar 24, 2026
BCDA Earnings Call Summary for Q4,2025
  • Phase III Success: CardiAMP HF trial shows statistically significant LV volume reduction in high-stress subgroup (p=0.02/0.01), supporting FDA/Q-Submission.
  • Regulatory Momentum: Q-Submission expected soon; Japan PMDA consultation and FDA De Novo review underway.
  • Financial Stability: 2025 cash of $2.5M with modest R&D growth planned for 2026.
  • Competitive Edge: Minimally invasive delivery and robust data position CardiAMP as leading cell therapy.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Biocardia (BCDA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Biocardia (BCDA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Biocardia (BCDA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Biocardia (BCDA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Biocardia (BCDA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Biocardia (BCDA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield